WEBULL
WebtradeDownload

Insulet (PODD) Could Be 8% Undervalued Following Conference Spotlight

Simply Wall St · 1d ago

Insulet (PODD) drew fresh attention after management scheduled a presentation at the 2026 Jefferies Global Healthcare Conference in London on November 18, with a webcast available through its investor relations site.

The recent conference spotlight comes after a sharp rebound in momentum, with the share price logging a 30-day return of 17.59% and a 90-day share price gain of 16.21%. This comes even though the year-to-date share price return is down 45.26% and the 1-year total shareholder return has declined 51.65%.

Scan how Insulet compares by reviewing a hand picked group of diabetes and medtech peers with resilient balance sheets in our list of solid balance sheet and fundamentals (23 results)

Insulet has staged a sharp bounce, yet the longer term returns remain deeply negative. Is this latest upswing a catch up to business fundamentals, or just a reset in sentiment that the valuation now needs to justify?

Most Popular Narrative: 7% Undervalued

On the Simply Wall St narrative, Insulet screens as undervalued, with a fair value of $167.17 against the latest close of $154.86. That gap has investors asking whether the recent share price rebound is just the start of sentiment catching up to the underlying thesis.

Analysts expect earnings to reach $675.9 million (and earnings per share of $9.93) by about October 2029, up from $375.3 million today.

In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.5x on those 2029 earnings, down from 25.8x today.

See why 23 investors see Insulet as 7% undervalued.

Result: Fair Value of $167.17 (UNDERVALUED)

Still, the Insulet narrative hinges on improving weaker type 2 patient retention and managing recall-related reputational risk, which could pressure pod usage and future expectations.

Find out about the key risks to this Insulet narrative.

Next Steps

With sentiment split between a bruising 1 year return and a recent rebound, it makes sense to move fast and test the story against the numbers yourself. To see what the optimistic side of the ledger looks like, start by reviewing the 3 key rewards.

Looking for more Insulet-sized ideas?

If you only stop at Insulet, you risk missing other opportunities that fit your style. Put the same discipline to work across the market using targeted screeners.